| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(元) | 172,044,678.35 | - | 150,213,803.47 | - | 384,581,465.30 |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(元) | 9,463,588.85 | - | 14,285,842.36 | - | 7,641,649.78 |
| 试剂盒销售收入(元) | 34,815.40 | - | 10,873.79 | - | 81,281.55 |
| 医药推广收入(元) | - | - | 33,718,375.75 | - | 6,903,018.87 |
| 推广服务(元) | - | 86,583,197.30 | - | 32,245,566.04 | - |
| 医药产品销售(元) | - | 498,847,373.11 | - | 550,103,887.96 | - |
| 结核菌素纯蛋白衍生物(半成品)(元) | 296,351.83 | - | - | - | - |
| 医药推广服务收入(元) | 65,685,971.96 | - | - | - | - |
| 营业成本(元) | |||||
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(元) | 7,958,148.29 | - | 5,022,878.91 | - | 13,116,275.36 |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(元) | 2,749,821.13 | - | 1,386,768.06 | - | 1,280,787.73 |
| 试剂盒销售收入(元) | 30,815.62 | - | 3,472.00 | - | 29,520.67 |
| 医药推广收入(元) | - | - | 19,519,575.00 | - | 3,747,860.48 |
| 推广服务(元) | - | 49,154,143.86 | - | 15,903,336.46 | - |
| 医药产品销售(元) | - | 25,570,163.09 | - | 22,098,644.39 | - |
| 结核菌素纯蛋白衍生物(半成品)(元) | 600.00 | - | - | - | - |
| 医药推广服务收入(元) | 34,375,071.24 | - | - | - | - |
| 毛利(元) | |||||
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(元) | 164,086,530.06 | - | 145,190,924.56 | - | 371,465,189.94 |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(元) | 6,713,767.72 | - | 12,899,074.30 | - | 6,360,862.05 |
| 试剂盒销售收入(元) | 3,999.78 | - | 7,401.79 | - | 51,760.88 |
| 医药推广收入(元) | - | - | 14,198,800.75 | - | 3,155,158.39 |
| 推广服务(元) | - | 37,429,053.44 | - | 16,342,229.58 | - |
| 医药产品销售(元) | - | 473,277,210.02 | - | 528,005,243.57 | - |
| 结核菌素纯蛋白衍生物(半成品)(元) | 295,751.83 | - | - | - | - |
| 医药推广服务收入(元) | 31,310,900.72 | - | - | - | - |
| 毛利率(%) | |||||
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(%) | 95.37 | - | 96.66 | - | 96.59 |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(%) | 70.94 | - | 90.29 | - | 83.24 |
| 试剂盒销售收入(%) | 11.49 | - | 68.07 | - | 63.68 |
| 医药推广收入(%) | - | - | 42.11 | - | 45.71 |
| 推广服务(%) | - | 43.23 | - | 50.68 | - |
| 医药产品销售(%) | - | 94.87 | - | 95.98 | - |
| 结核菌素纯蛋白衍生物(半成品)(%) | 99.80 | - | - | - | - |
| 医药推广服务收入(%) | 47.67 | - | - | - | - |
| 收入构成(%) | |||||
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(%) | 69.51 | - | 75.78 | - | 96.34 |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(%) | 3.82 | - | 7.21 | - | 1.91 |
| 试剂盒销售收入(%) | 0.01 | - | 0.01 | - | 0.02 |
| 医药推广收入(%) | - | - | 17.01 | - | 1.73 |
| 推广服务(%) | - | 14.79 | - | 5.54 | - |
| 医药产品销售(%) | - | 85.21 | - | 94.46 | - |
| 结核菌素纯蛋白衍生物(半成品)(%) | 0.12 | - | - | - | - |
| 医药推广服务收入(%) | 26.54 | - | - | - | - |
| 毛利构成(%) | |||||
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(%) | 81.07 | - | 84.27 | - | 97.49 |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(%) | 3.32 | - | 7.49 | - | 1.67 |
| 试剂盒销售收入(%) | 0.00 | - | 0.00 | - | 0.01 |
| 医药推广收入(%) | - | - | 8.24 | - | 0.83 |
| 推广服务(%) | - | 7.33 | - | 3.00 | - |
| 医药产品销售(%) | - | 92.67 | - | 97.00 | - |
| 结核菌素纯蛋白衍生物(半成品)(%) | 0.15 | - | - | - | - |
| 医药推广服务收入(%) | 15.47 | - | - | - | - |